POLR3D

Across TCGA pan-cancer cohorts, POLR3D Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated POLR3D data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher POLR3D Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated POLR3D expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LIHC, CESC, and UCEC are the cancer types where POLR3D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.046	0.553	<.001	18	view →
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	16	view →
UCEC	DFS	Median	All	0.957	0.628	.032	4	view →
SKCM	DFS	Median	II,III,IV	1.000	0.683	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

POLR3D–LIHC (DFS)

Open the LIHC breakdown →